| 產(chǎn)品編號 | bs-3860R-Cy5 |
| 英文名稱1 | Rabbit Anti-CHRDL2/Cy5 Conjugated antibody |
| 中文名稱 | Cy5標記的乳腺腫瘤新因子1抗體 |
| 別 名 | BNF1; Breast tumor novel factor 1; CHL2; chordin like 2; Chordin like protein 2 precursor; Chordin related protein 2; CRDL2_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 免疫學 生長因子和激素 血管內(nèi)皮細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Cow, Sheep, ) |
| 產(chǎn)品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 45kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CHRDL2 C-terminus |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: CHRDL2 is a novel chordin like protein that can act as a BMP antagonist. A member of the chordin family of proteins, it contains a signal peptide and three CR (cysteine-rich repeat) domains. When expressed as a recombinant protein it is secreted and binds to activin A, but not to BMP-2, -4, -6. Differential expression has been detected in developing chondrocytes, myoblasts, osteoblasts, and osteoarthritic joints. Complex alternative splicing of CHRDL2 potentially results in distinct isoforms that differ at their C termini, in the expression of signal peptide, and in the content of CR domains. CHRDL2 was originally characterized as a novel protein exclusively expressed in breast, lung, and colon tumors. Function: May inhibit BMPs activity by blocking their interaction with their receptors. Has a negative regulator effect on the cartilage formation/regeneration from immature mesenchymal cells, by preventing or reducing the rate of matrix accumulation (By similarity). Implicated in tumor angiogenesis. May play a role during myoblast and osteoblast differentiation, and maturation. Subunit: Interacts with GDF5 (By similarity). May interact with BMP2, BMP4, BMP5, BMP6, BMP7 and INHBA. Subcellular Location: Isoform 1: Secreted (Potential). Isoform 2: Secreted (Potential). Isoform 3: Cytoplasm (Potential). Isoform 4: Cytoplasm (Potential). Isoform 5: Cytoplasm (Potential). Tissue Specificity: Highly expressed in uterus. Moderately expressed in heart, liver, prostate, testis and ovary. Weakly expressed in skeletal muscle, kidney, spleen, small intestine and colon. Expressed in the secretory epithelial cells of uterine endometrium, fallopian tubes, endocervical glands, bladder and prostate, as well as the transitional epithelium of the urinary bladder, and in bone osteoblasts (at protein level). In normal cartilage, expression was confined in a few chondrocytes in the superficial zone as well as in the middle zone. In diseased cartilage coming from osteoarthritic patients, expression was limited to the middle zone of chondrocytes. Isoform 1 and isoform 2 are expressed in fetal cerebellum and heart, while only isoform 2 is detected in fetal spleen. Isoform 2 present in plasma. Post-translational modifications: Phosphorylation sites are present in the extracellular medium. Isoform 2 is phosphorylated on Ser-402. Similarity: Contains 3 VWFC domains. Database links: Entrez Gene: 25884 Human Omim: 613127 Human SwissProt: Q6WN34 Human Unigene: 432379 Human
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CHRDL2原來主要用于乳腺癌的研究，近年來研究發(fā)現(xiàn)在腫瘤中也有發(fā)現(xiàn)，目前在肺癌，結腸腫瘤的研究中應用較多。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
